Royal Bank of Canada’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Royal Bank of Canada’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-16	Closed	–	–	7772
2022 Q4	$0	Sell	16 -170	-91%	-$941	﹤0.01%	8057
2022 Q3	$1K	Buy	+186	New	+$1.17K	﹤0.01%	7364
2020 Q2	–	Sell	-500	Closed	-$2K	–	7035
2020 Q1	$2K	Sell	500 -45	-8%	-$233	﹤0.01%	6362
2019 Q4	$3K	Hold	545	–	–	﹤0.01%	6514
2019 Q3	$7K	Hold	545	–	–	﹤0.01%	5918
2019 Q2	$8K	Sell	545 -1	-0.2%	-$27	﹤0.01%	6136
2019 Q1	$23K	Sell	546 -17	-3%	-$716	﹤0.01%	5602
2018 Q4	$24K	Sell	563 -64	-10%	-$2.88K	﹤0.01%	5511
2018 Q3	$30K	Buy	627 +78	+14%	+$3.91K	﹤0.01%	5484
2018 Q2	$26K	Buy	549 +4	+0.7%	+$222	﹤0.01%	5436
2018 Q1	$34K	Sell	545 -7	-1%	-$369	﹤0.01%	5237
2017 Q4	$29K	Buy	552 +507	+1,127%	+$30.2K	﹤0.01%	5430
2017 Q3	$3K	Hold	45	–	–	﹤0.01%	6532
2017 Q2	$2K	Buy	+45	New	+$2.08K	﹤0.01%	6312

Royal Bank of Canada's FSTX Position: Q1 2023 in Review

Royal Bank of Canada sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 16 shares.

Royal Bank of Canada first reported a position in FSTX in Q2 2017 and held it in 14 quarters. The position peaked at $34K in Q1 2018. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

Royal Bank of Canada reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Royal Bank of Canada sold 16 F-star Therapeutics, Inc. Common Stock shares in Q1 2023.
Royal Bank of Canada first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2017 and held it in 14 quarters.
Royal Bank of Canada's F-star Therapeutics, Inc. Common Stock position peaked at $34K in Q1 2018.
0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Royal Bank of Canada's 13F filing for Q1 2023, filed 15 May 2023.